Finerenone: a breakthrough mineralocorticoid receptor antagonist for heart failure, diabetes and chronic kidney disease
2024

Finerenone: A New Treatment for Heart Failure and Kidney Disease

Sample size: 1066 publication 10 minutes Evidence: moderate

Author Information

Author(s): Pradhan Akshyaya, Tripathi Umesh Chandra

Primary Institution: King George’s Medical University, Lucknow, Uttar Pradesh, India

Hypothesis

Can Finerenone improve cardiovascular outcomes and renal function in patients with heart failure and diabetes?

Conclusion

Finerenone is a novel mineralocorticoid receptor antagonist that shows promise in improving kidney function and reducing heart failure events with fewer side effects compared to older treatments.

Supporting Evidence

  • Finerenone has been shown to improve renal function in patients with chronic kidney disease and diabetes.
  • It reduces the risk of heart failure events with fewer side effects compared to older medications.
  • Clinical trials indicate that Finerenone is effective in reducing albuminuria.

Takeaway

Finerenone is a new medicine that helps people with heart problems and diabetes by making their kidneys work better and reducing heart issues.

Methodology

The article reviews the properties of Finerenone and compares it with existing mineralocorticoid receptor antagonists, focusing on its effects in patients with chronic kidney disease and diabetes.

Potential Biases

Potential bias in reporting outcomes from trials may exist.

Limitations

More randomized studies are needed to confirm the benefits of Finerenone in heart failure patients.

Participant Demographics

Patients with chronic kidney disease and diabetes, including those with heart failure.

Statistical Information

P-Value

0.42–0.88

Confidence Interval

95% CI 0.56–0.90

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/s43044-024-00586-z

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication